+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Antispasmodics Drugs Market by Drug type (Dicyclomine Hydrochloride, Hyoscyamine, Loperamide Hydrochloride), Route of administration (Injectable, Oral, Sublingual), Distribution Channel, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5336390
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antispasmodics Drugs Market size was estimated at USD 13.57 billion in 2023, USD 14.70 billion in 2024, and is expected to grow at a CAGR of 8.36% to reach USD 23.83 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antispasmodics Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antispasmodics Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antispasmodics Drugs Market, highlighting leading vendors and their innovative profiles. These include Actiza Pharmaceutical Private Limited, Ambrosia Pharma, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, B JOSHI AGROCHEM PHARMA, Blue Cross Laboratories Pvt Ltd., Daiichi Sankyo Company, Limited, Dr. Reddys Laboratories Ltd., Flamingo Pharmaceuticals Ltd, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnsons & Johnsons Services Inc., Lexicare Pharma Pvt. Ltd., McKesson Medical-Surgical Goverment Solutions LLC, Mylan N.V., Nexus Pharmaceuticals Inc., Noreva Biotech, Pfizer Inc., Sanofi SA, Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Wellona Pharma Private Limited.

Market Segmentation & Coverage

This research report categorizes the Antispasmodics Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug type
    • Dicyclomine Hydrochloride
    • Hyoscyamine
    • Loperamide Hydrochloride
  • Route of administration
    • Injectable
    • Oral
    • Sublingual
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End-User
    • Hospitals
    • Speciality Centres
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Antispasmodics Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antispasmodics Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Antispasmodics Drugs Market?
  4. What is the market share of the leading vendors in the Antispasmodics Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Antispasmodics Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antispasmodics Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High incidences of irritable bowel syndrome and abdominal problems
5.1.1.2. Increasing patient awareness level and improvement in treatment
5.1.1.3. Rising antispasmodic medicines approvals worldwide
5.1.2. Restraints
5.1.2.1. Patent expiration issues of antispasmodic drugs
5.1.3. Opportunities
5.1.3.1. Growing investment in research and development of novel antispasmodic meds
5.1.3.2. Investment and expansion of generic drugs production facilities
5.1.4. Challenges
5.1.4.1. Inappropriate use of skeletal muscle relaxants in geriatric patients
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Antispasmodics Drugs Market, by Drug type
6.1. Introduction
6.2. Dicyclomine Hydrochloride
6.3. Hyoscyamine
6.4. Loperamide Hydrochloride
7. Antispasmodics Drugs Market, by Route of administration
7.1. Introduction
7.2. Injectable
7.3. Oral
7.4. Sublingual
8. Antispasmodics Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Antispasmodics Drugs Market, by End-User
9.1. Introduction
9.2. Hospitals
9.3. Speciality Centres
10. Americas Antispasmodics Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Antispasmodics Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Antispasmodics Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Actiza Pharmaceutical Private Limited
14.1.2. Ambrosia Pharma
14.1.3. Amneal Pharmaceuticals LLC
14.1.4. Aurobindo Pharma Limited
14.1.5. B JOSHI AGROCHEM PHARMA
14.1.6. Blue Cross Laboratories Pvt Ltd.
14.1.7. Daiichi Sankyo Company, Limited
14.1.8. Dr. Reddys Laboratories Ltd.
14.1.9. Flamingo Pharmaceuticals Ltd
14.1.10. Fresenius Kabi AG
14.1.11. GlaxoSmithKline PLC
14.1.12. Hikma Pharmaceuticals PLC
14.1.13. Johnsons & Johnsons Services Inc.
14.1.14. Lexicare Pharma Pvt. Ltd.
14.1.15. McKesson Medical-Surgical Goverment Solutions LLC
14.1.16. Mylan N.V.
14.1.17. Nexus Pharmaceuticals Inc.
14.1.18. Noreva Biotech
14.1.19. Pfizer Inc.
14.1.20. Sanofi SA
14.1.21. Solitaire Pharmacia Private Limited
14.1.22. Strides Pharma Science Limited
14.1.23. Sun Pharmaceutical Industries Ltd.
14.1.24. Takeda Pharmaceutical Company Limited
14.1.25. Wellona Pharma Private Limited
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. ANTISPASMODICS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTISPASMODICS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTISPASMODICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTISPASMODICS DRUGS MARKET DYNAMICS
FIGURE 7. ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ANTISPASMODICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. ANTISPASMODICS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • Actiza Pharmaceutical Private Limited
  • Ambrosia Pharma
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • B JOSHI AGROCHEM PHARMA
  • Blue Cross Laboratories Pvt Ltd.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddys Laboratories Ltd.
  • Flamingo Pharmaceuticals Ltd
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnsons & Johnsons Services Inc.
  • Lexicare Pharma Pvt. Ltd.
  • McKesson Medical-Surgical Goverment Solutions LLC
  • Mylan N.V.
  • Nexus Pharmaceuticals Inc.
  • Noreva Biotech
  • Pfizer Inc.
  • Sanofi SA
  • Solitaire Pharmacia Private Limited
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wellona Pharma Private Limited

Methodology

Loading
LOADING...

Table Information